Currently approved PAH drugs such as prostacyclin analogues, endothelin receptor antagonists and phosphodiesterase-5 (PDE-5) inhibitors aim to control pulmonary vascular tone (Olsson and Hoeper, 2009). The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.